echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Clinical study of Berzosertib combined with cisplatin in the treatment of patients with advanced solid tumors

    Br J Cancer: Clinical study of Berzosertib combined with cisplatin in the treatment of patients with advanced solid tumors

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The standard care treatments used to treat a variety of tumors mainly include DNA damage-related chemotherapy drugs.


    The standard care treatments used to treat a variety of tumors mainly include DNA damage-related chemotherapy drugs.


    Previous studies have shown, the ATR (ataxia capillary blood vessel dilation mutated (ATM) and Rad3 related protein kinase) play a crucial role in DNA damage response (DDR), which is capable of regulation by homologous recombination, and cell cycle checkpoint Repair of damaged DNA.


    Blood vessel



    Berzosertib (M6620, VX-970) is a highly effective and selective ATR inhibitor.


    Berzosertib (M6620, VX-970) is a highly effective and selective ATR inhibitor.



    Related research flow chart

    Related research flow chart

    The results showed that a total of 31 patients received berzosertib on seven dose levels (90-210μmg / m2) and cisplatin (40-75μmg / m 2 ) in combination therapy.


    2



    Plasma concentration-time curve of Berzosertib combined with cisplatin

    Plasma concentration-time curve of Berzosertib combined with cisplatin

    All in all, the results of the study reveal that the combination therapy of berzosertib and cisplatin is well tolerated, and it has shown preliminary clinical activity in patients with advanced solid tumors.


    The combination therapy of berzosertib and cisplatin is well tolerated, and it has shown preliminary clinical activity in patients with advanced solid tumors.



    Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours

     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.